Medigene AG (ETR:MDG1 – Get Free Report)’s stock price traded down 6.3% during trading on Wednesday . The company traded as low as €1.76 ($1.87) and last traded at €1.85 ($1.96). 32,043 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 306,207 shares. The stock had previously closed at €1.97 ($2.10).
Medigene Price Performance
The stock has a market capitalization of $47.16 million, a P/E ratio of -2.91, a PEG ratio of 7.12 and a beta of 0.85. The company has a debt-to-equity ratio of 14.00, a quick ratio of 5.85 and a current ratio of 2.53. The firm has a fifty day moving average price of €1.78 and a two-hundred day moving average price of €1.63.
Medigene Company Profile
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Recommended Stories
- Five stocks we like better than Medigene
- Stock Market Upgrades: What Are They?
- Comprehensive Analysis of PayPal Stock
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- What are earnings reports?
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.